268600.KQ Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 Mar 2023 @ 02:30):

Cellivery Therapeutics, Inc. researches and develops therapeutic drugs for life-threatening lethal diseases, such as cancer, inflammation, metabolic, and neurodegenerative diseases...

Stats
Today's Volume	0.00
Average Volume	1.15M
Market Cap	244.94B
EPS	KRW0 ( 2024-03-21 )
Next earnings date	( KRW0 ) 2024-05-12
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW904.38 (13.54%)

Volume Correlation

Long: 0.03 (neutral)

Short: -0.87 (strong negative)

Signal:(24.963) Be Aware. Possible trading coming up! (swing)

Cellivery Therapeutics, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cellivery Therapeutics, Correlation - Currency/Commodity

-0.64
( weak negative )

-0.53
( weak negative )

-0.43
( neutral )

-0.04
( neutral )

-0.28
( neutral )

0.37
( neutral )

Cellivery Therapeutics, Financials

Annual	2023
Revenue:	KRW18.86B
Gross Profit:	KRW-3.78B (-20.02 %)
EPS:	KRW-889.35

Q4	2023
Revenue:	KRW18.00B
Gross Profit:	KRW-631.89M (-3.51 %)
EPS:	KRW-395.91

Q3	2023
Revenue:	KRW54.20M
Gross Profit:	KRW-1.31B (-2 424.62 %)
EPS:	KRW-106.66

Q2	2023
Revenue:	KRW5.55M
Gross Profit:	KRW-1.12B (-20 169.24 %)
EPS:	KRW-334.94

Financial Reports:

No articles found.

Cellivery Therapeutics,

Cellivery Therapeutics, Inc. researches and develops therapeutic drugs for life-threatening lethal diseases, such as cancer, inflammation, metabolic, and neurodegenerative diseases. It develops small molecule, antibody, and vaccine drugs based on its Therapeutic molecule Systemic Delivery Technology. The company was founded in 2014 and is based in Seoul, South Korea.